1. Market Research
  2. > Pharmaceutical
  3. > Biopharmaceutical Market Trends
Asia Pacific Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Therapy Type, Product, Technology, Application, and End User, and Country

Asia Pacific Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Therapy Type, Product, Technology, Application, and End User, and Country

  • February 2021
  • 108 pages
  • ID: 6027771
  • Format: PDF
  • The Insight Partners
Up to $1000 off Until Apr 20th 2021


Table of Contents

Search Inside

The Asia Pacific cell therapy market is expected to reach US$ 1,366.0 million by 2027 from US$ 2,449.8 million in 2019. The market is estimated to grow at a CAGR of 7.7% from 2020-2027.

Japan held the significant market share in 2019.Hospitals and healthcare facilities in Japan provide high-quality healthcare and are affordable to people as Japan has the Universal Healthcare Plan.

Hospitals in the country are larger, and they offer several specializations in their premises. For instance, Tokatsu Dialysis Hospital & Clinics (a private hospital) offers 14 different medical specialties such as nephrology, cardiovascular, gastroenterological surgery, and orthopedics.
Moreover, the rising geriatric population and declining birth rate in Japan has led the government to announce the Japan vision for healthcare in 2035 plan.This initiative allows a patient to reimburse 70-90% of its treatment cost from its insurer or government, and the remaining amount had to pay by a patient.

This has led to an increasing number of a patient undergoing various therapies and procedures at the hospitals. With these initiatives to support population health, the market for cell therapy is likely to grow in the forecast period.
The Japanese healthcare industry is currently witnessing massive developments and financial aids to accelerate the adoption and acceptance of cell therapy-based products.The government is focused on developing laws and policies to bolster the innovations and discoveries in novel diagnostics and therapeutics, such as regenerative medicine.

An increasing number of partnerships and distribution agreements are likely to consolidate product reach in Japan. For instance, in February 2018, FUJIFILM Corporation and Takeda Pharmaceutical Company Ltd collaborated to develop regenerative medicine therapies utilizing cardiomyocytes derived from iPSC for the treatment of heart failure.
Moreover, in January 2019, Takeda Pharmaceutical Company Ltd entered into the collaboration with Memorial Sloan Kettering Cancer Center (MSK) to explore and develop novel chimeric antigen receptor T-cell (CAR-T) products that have application in the treatment of indications such as multiple myeloma, acute myeloid leukemia, and additional solid tumor. Thus, the active involvement toward the developments related to cell therapy by the companies based in the country is expected to drive the cell therapy market during the forecast years.

Exhibit: Cell Therapy Market in Japan Revenue and Forecast to 2027 (US$ Million)


By Therapy Type
• Allogeneic
• Autologous
By Product
• Consumables
• Equipment
• Systems and Software
By Technology
• Viral Vector Technology
• Genome Editing Technology
• Somatic Cell Technology
• Cell Immortalization Technology
• Cell Plasticity Technology
• Three-Dimensional Technology
By Application
• Oncology
• Cardiovascular
• Orthopedic
• Wound Management
• Other Applications

By End User
• Research Institutes
• Hospitals
• Others
By Country
• Japan
• China
• India
• Australia
• South Korea
• Rest of APAC

Company Profiles
• Vericel Corporation
• NuVasive, Inc.
• Mesoblast Limited
• JCR Pharmaceuticals Co. Ltd.
• Smith & Nephew
• Bristol-Myers Squibb Company
• Cells for Cells
• Stemedica Cell Technologies, Inc
• Castle Creek Biosciences, Inc.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Europe Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Therapy Type ; Product ; Technology ; Application ; End User, and Country.

  • $ 3000
  • February 2021
  • 165 pages

The Europe cell therapy market is expected to reach US$ 3,610.7 million by 2027 from US$ 2,125.7 million in 2019; it is anticipated to grow at a CAGR of 6.9% during 2019-2027. The growth of the Europe ...

  • Europe
  • United Kingdom
  • Cell Therapy
  • Industry analysis
  • Chronic Disease Prevalence
  • Cause-Specific Mortality Rate


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on